Envista Holdings Corporation header image

Envista Holdings Corporation

NVST

Equity

ISIN null / Valor 49153522

New York Stock Exchange, Inc (2026-05-26)
USD 23.50+0.30%

Envista Holdings Corporation
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Envista Holdings Corporation is a global leader in the dental industry, offering a comprehensive range of products and technologies through its Specialty Products & Technologies and Equipment & Consumables divisions. The Specialty Products & Technologies division manufactures dental implant systems, prosthetics, clear aligners, orthodontic brackets and wires, as well as laboratory and related technologies. Meanwhile, the Equipment & Consumables segment produces essential dental office equipment and supplies, including digital imaging systems, restorative and endodontic materials, bonding agents, cements, and infection prevention products. With a portfolio of over 30 trusted brands, Envista supports dental professionals by providing innovative solutions and integrated digital workflows that enhance patient care and streamline dental practice operations.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (19.05.2026):

Envista Holdings Corporation — Q1 2026: Envista reported a strong start to 2026 with first‑quarter sales of $705.5 million and 9.5% core sales growth versus Q1 2025. The company delivered higher profitability (GAAP diluted EPS $0.23; adjusted diluted EPS $0.36, +50% year‑over‑year) and improved margins, while reaffirming full‑year 2026 guidance and announcing an incremental $300 million share‑repurchase program.

Revenue and growth

Sales were $705.5 million in Q1 2026 with core sales growth of 9.5% (total sales growth 14.4% with negative currency and minor acquisition impacts). Specialty Products & Technologies sales were $457.8M (core growth 8.4%) and Equipment & Consumables were $247.7M (core growth 11.5%).

Profitability and margins

GAAP net income was $38.7 million (GAAP diluted EPS $0.23). Adjusted net income was $60.0 million and adjusted diluted EPS was $0.36 (+50% YoY). Adjusted EBITDA was $98.9 million (+25% YoY) with an adjusted EBITDA margin of 14.0%, up ~120 basis points year‑over‑year.

Operations and investments

Gross profit rose to $390.1M and operating profit to $62.5M. Envista cited the Envista Business System (EBS) as supporting ~100 bps of gross margin and ~120 bps of adjusted EBITDA expansion. R&D spending increased (Q1 R&D $30.0M vs $25.3M a year earlier) and the company said it increased Sales & Marketing investment as part of its strategic priorities.

Cash flow and balance sheet

Operating cash flow was negative $3.3M and free cash flow was negative $15.7M in Q1 2026 (versus roughly breakeven and negative $5.1M in Q1 2025). Cash and cash equivalents totaled $1,082.8M at quarter end; long‑term debt was $1,439.1M and total stockholders’ equity was $3,079.5M.

Capital returns

During Q1 the company repurchased 1.6 million shares for approximately $43M (about $41M remaining under the then‑existing program). On May 5, 2026 the Board authorized an incremental $300M share repurchase program through December 31, 2029.

Outlook

Envista reaffirmed full‑year 2026 guidance: core sales growth 2%–4%, adjusted EBITDA growth 7%–13%, adjusted diluted EPS $1.35–$1.45, and free cash conversion of ~100%. The company noted it does not provide GAAP forward‑looking estimates.

Summarized from source with an LLMView Source

Key figures

40.6%1Y
-29.4%3Y
-46.2%5Y

Performance

39.3%1Y
38.5%3Y
35.7%5Y

Volatility

Market cap

3824 M

Market cap (USD)

Daily traded volume (Shares)

4,642,908

Daily traded volume (Shares)

1 day high/low

19.23 / 18.78

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Fresenius Medical Care AG
Fresenius Medical Care AG Fresenius Medical Care AG Valor: 523134
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.28%USD 21.58
Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.01%USD 21.35
DENTSPLY SIRONA Inc
DENTSPLY SIRONA Inc DENTSPLY SIRONA Inc Valor: 31773200
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.15%USD 9.99
Elevance Health Inc
Elevance Health Inc Elevance Health Inc Valor: 26124340
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.73%USD 387.85
Sanofi SA
Sanofi SA Sanofi SA Valor: 1447201
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.32%USD 44.15
Intuitive Surgical Inc
Intuitive Surgical Inc Intuitive Surgical Inc Valor: 1631646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.33%USD 436.64
Icon PLC
Icon PLC Icon PLC Valor: 1017575
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.51%USD 113.85
Acadia Healthcare Co Inc
Acadia Healthcare Co Inc Acadia Healthcare Co Inc Valor: 14151414
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.34%USD 23.49
Surgery Partners Inc
Surgery Partners Inc Surgery Partners Inc Valor: 29308003
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.37%USD 13.45
Olaplex Holdings Inc
Olaplex Holdings Inc Olaplex Holdings Inc Valor: 113471584
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.49%USD 2.04